Literature DB >> 8102353

Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.

K Y Tsang1, S V Kashmiri, C F Qi, C Nieroda, B Calvo, R De Filippi, J W Greiner, F J Primus, J Schlom.   

Abstract

cDNA encoding the human IL gene (580 bp), inserted into a retroviral expression vector carrying neomycin resistance selective marker, was introduced into HT-29 human colon carcinoma cells by lipofection. Interleukin-6 activity was measured by ELISA and bioassay using B9 cells. Interleukin-6 secreted by transfected HT-29 cells was shown to be biologically active. The expression of the human tumor associated antigen CEA (carcinoembryonic antigen), HLA classes I and II, and ICAM-1 antigens in the transfected HT-29 cells were also analyzed by flow cytometry. Significant enhancement in the expression of CEA but not in the expression of HLA class I, HLA class II and ICAM-1 antigens, was observed in the transfected HT-29 cells as compared to the parental HT-29 cells. These results provide experimental evidence that enhancement of tumor antigen expression on tumor cells can be induced by IL-6 gene transfection, and suggest another potential role for the use of IL-6 gene transfer in the immunotherapy of human cancers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102353     DOI: 10.1016/0165-2478(93)90050-c

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  Tumor growth inhibition effect of hIL-6 on colon cancer cells transfected with the target gene by retroviral vector.

Authors:  Bing Xiao; Bo Jing; Ya-Li Zhang; Dian-Yuan Zhou; Wan-Dai Zhang
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.